Julian J Haynes

"For the (qual/quan) concept to truly revolutionize drug discovery, a way must be found to successfully combine the expertise encompassed within the biotransformation and high-throughput bioana lysis disciplines."

A. Nedderman, M. Gleave, Julian J Haynes, 2012 .

Simultaneous qualitative and quantitative metabolism data generation: a convenient marriage?

A. Nedderman, M. Savage, M. Gleave, 2012, Bioanalysis.

Utilization of DBS within drug discovery: a simple 2D-LC-MS/MS system to minimize blood- and paper-based matrix effects from FTA elute™ DBS.

Julian J Haynes, G. Clark, 2011, Bioanalysis.

Utilization of DBS within drug discovery: development of a serial microsampling pharmacokinetic study in mice.

M. Bayliss, Julian J Haynes, G. Clark, 2010, Bioanalysis.

No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV‐1–Infected Subjects

J. Marshall, P. Chan, S. Nepal, 2018, Journal of clinical pharmacology.

Bioanalytical determination of unstable endogenous small peptides: RFRP3 and its metabolites in rat blood.

Julian J Haynes, G. Clark, Hannah B L Jones, 2011, Bioanalysis.